Sanofi forecasting moderate profit growth
Sanofi has forecast moderate earnings growth that undershot expectations, saying demand for bestselling asthma and eczema drug Dupixent would be partly offset by competition for its multiple sclerosis pill Aubagio and product launch costs.
Business
• 03 Feb 23
